- Global Pharma News & Resources

Promius Pharma Announces Launch of "My Skin Matters," An Empowerment Movement for People with Skin Conditions

Promius Pharma Announces Launch of "My Skin Matters," An Empowerment Movement for People with Skin Conditions

PR Newswire

PRINCETON, N.J., Oct. 29, 2018

PRINCETON, N.J., Oct. 29, 2018 /PRNewswire/ -- Promius Pharma announced today the launch of My Skin Matters, a fearless movement for people living with eczema, psoriasis, acne, and other skin conditions. With its rallying cry of "I've Got Nothing to Hide," "My Skin Matters" helps people with skin conditions live without fear and shame, and find support in an online community where they can share stories, experiences, and tips.

In addition to the "My Skin Matters" website, three social media communities help drive the movement by enabling people with skin conditions to stand up, speak out, and be heard. Facebook, Instagram, and Twitter pages for "My Skin Matters" keep the conversation going about the importance of having a positive self-image and being uninhibited by skin conditions. When people share their experiences using #MySkinMatters, they will have a chance of being featured on the "My Skin Matters" website.

"At Promius Pharma, we believe every patient is a person first. That's why we are committed to helping patients with skin conditions be proud of who they are," explained Garth Thomas, Dermatology Sales & Marketing Head at Promius Pharma. "'My Skin Matters' reframes the conversation about skin conditions in a positive and empowering way and demonstrates our leadership in dermatology on behalf of the patients we serve."

As a social movement, "My Skin Matters" also aims to build partnerships with patient advocacy organizations and to support community events focused on skin health.

Join the movement and sign up for updates about it at

About Promius Pharma LLC
Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues. The company assumes no obligation to update any information contained herein.

Contact information:
Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540

Investor Relations:
Ashish Girotra (USA)
+1 (609) 375-6145

Media Relations:
Lori McCreary (USA)
+1 (609) 375-2955

Copyright 2018 Promius Pharma, LLC

View original content to download multimedia:

SOURCE Promius Pharma LLC

Editor Details

Last Updated: 29-Oct-2018